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Mitogen-activated protein (MAP) kinases are a family of serine/threonine kinases that play a central role in transducing extracellular cues into a
variety of intracellular responses ranging from lineage specification to cell division and adaptation. Fourteen MAP kinase genes have been
identified in the human genome, which define 7 distinct MAP kinase signaling pathways. MAP kinases can be classified into conventional or
atypical enzymes, based on their ability to get phosphorylated and activated by members of the MAP kinase kinase (MAPKK)/MEK family.
Conventional MAP kinases comprise ERK1/ERK2, p38s, JNKs, and ERK5, which are all substrates of MAPKKs. Atypical MAP kinases include
ERK3/ERK4, NLK and ERK7. Much less is known about the regulation, substrate specificity and physiological functions of atypical MAP
kinases.
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Mitogen-activated protein (MAP) kinase pathways are ubiqui-
tous signaling modules by which cells transduce extracellular
chemical and physical signals into adaptive intracellular responses
[1–3]. These modules are classically organized into an architecture
of three sequentially acting protein kinases comprising a MAP
kinase kinase kinase (MAPKKK), a MAP kinase kinase (MAPKK
or MEK), and the effector MAP kinase itself. Once activated,
MAP kinases phosphorylate a wide range of substrates present in
various subcellular compartments. The efficiency and specificity
of signal transmission through MAP kinase pathways is ensured
by docking interactions between individual components of the
pathway and by scaffolding proteins [4,5].
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genes have been identified that define 7 distinct MAP kinase
pathways (Fig. 1). Pharmacological and genetic studies have
revealed that these pathways control numerous cellular
processes, such as tissue morphogenesis, cell proliferation
and differentiation, cell survival, immune responses, and
adaptation [3,6–8]. The archetype MAP kinase pathway is
the extracellular signal-regulated kinase 1 (ERK1)/ERK2
module, which is preferentially activated in response to
mitogenic factors. Typically, stimulation of growth factor
receptors leads to the activation of the small GTPase Ras,
which recruits the MAPKKK Raf to the membrane for
subsequent activation by phosphorylation. Activated Raf
isoforms phosphorylate and activate the dual-specificity
MAPKKs MEK1/MEK2, which in turn activate the MAP
kinases ERK1 and ERK2 by phosphorylation of the threonine
and tyrosine residues within the activation loop motif Thr–
Glu–Tyr. ERK1/ERK2 are proline-directed kinases that
phosphorylate target substrates on serine and threonine
residues followed by a proline [9–11]. More than 150
substrates of ERK1/ERK2 have been identified so far [12],
Fig. 1. Human MAP kinase pathways.
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vivo has been reported for only a minority of these proteins.
The specificity requirements of other MAP kinases are not as
well characterized.
2. Conventional and atypical MAP kinase family members
Phylogenetically, MAP kinases belong to the CMGC
group of protein kinases, which also includes the cyclin-
dependent kinases (CDKs), glycogen synthase kinases, and
CDK-like kinases [13]. Members of the MAP kinase branch
display more than 40% amino acid identity (60% similarity)
to ERK1 across the kinase domain. Individual MAP kinases
share a number of common structural and regulatory features,
but also have unique characteristics. One distinctive feature of
MAP kinases is the presence of a Thr–Xaa–Tyr motif in the
activation loop, which is the site of activating phosphoryla-
tion by the MAPKK family members MKK1–7. However,
not all MAP kinases are regulated in this way. This motif is
absent in ERK3, ERK4 and Nemo-like kinase (NLK), where
a glycine or glutamic acid residue replaces the tyrosine.
ERK7 contains the motif Thr–Glu–Tyr in the activation loop,
but there is no evidence that it is a substrate of the MAPKK
family. Instead, phosphorylation of this motif appears to be
catalyzed by ERK7 itself [14,15]. Thus, the different
subfamilies of MAP kinases (Fig. 1) are not always organized
into a classical three-tiered MAPKKK–MAPKK–MAP
kinase cascade. Here, we propose to classify MAP kinases
into conventional or atypical enzymes, based on their ability
to get phosphorylated and activated by MAPKK family
members. Conventional MAP kinases comprise ERK1/ERK2,
p38s, JNKs, and ERK5, which are all substrates of MAPKKs.
Atypical MAP kinases include ERK3/ERK4, NLK and
ERK7. Much less is known about the regulatory mechanisms
and physiological functions of atypical MAP kinases, which
are the focus of this review.3. ERK3/ERK4 subfamily
3.1. Discovery of ERK3 and ERK4 enzymes
ERK3 was cloned 15 years ago, alongside the extensively
studied MAP kinase ERK2, by homology screening of a rat brain
cDNA library using an ERK1-derived probe [16]. Later, the
sequences of the human [17,18] and mouse [19] orthologs were
reported. Intriguingly, the original rat ERK3 cDNA sequence
predicted a protein of 543-amino acids, whereas the human and
mouse cDNAs were found to encode a 721/720-amino acid
protein with a molecular mass of ∼100 kDa. Sequence
comparison showed that human/mouse and rat ERK3 sequences
were more than 90% identical over their shared length, but the
human/mouse proteins contained a C-terminal extension of 178
amino acids. However, close inspection of ERK3 sequences and
resequencing of the rat gene revealed that the originally published
rat sequence had a missing nucleotide between codons 502 and
503 [19,20]. Addition of a guanosine residue at this position shifts
the reading frame of rat ERK3, which now translates into a
protein of 720 amino acids with 94% identity to the human
protein. In vitro translation of the rat, mouse and human ERK3
cDNAs confirmed that all three genes encode proteins of
∼100 kDa. In agreement with these observations, in silico
analysis of the human and mouse genome sequence databases
demonstrated the presence of a single functional gene encoding
ERK3 [21]. Interestingly, database analysis has revealed the
presence of six MAPK6 (official name of the human ERK3 gene)
processed pseudogenes localized on four different chromosomes
[21]. This likely explains the presence of multiple ERK3-
hybridizing bands on Southern blots of human DNA.
A second human kinase with high homology to ERK3,
originally designated p63mapk, was cloned in 1992 also by virtue
of its homology to ERK1 [22]. The published p63mapk sequence
was reported to encode a protein of 557 amino acids. We have
renamed this kinase ERK4 in accordance with the nomenclature
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ERK3, resequencing of the human ERK4 cDNA and analysis of
genomic databases revealed that the original p63mapk sequence
contains five missing nucleotides (Meloche, S., Keyse, S.M. and
Seternes, O.M., unpublished data). Addition of these nucleotides
results in the substitution of four amino acids and also in a
frameshift within the C-terminus of ERK4, which now translates
into a 587-amino acid protein of molecular mass ∼70 kDa.
ERK4 is most closely related to the protein kinase ERK3 with
73% amino acid identity within the kinase domain. The atypical
MAP kinase ERK4 should not be mistaken for a 45-kDa anti-
ERK1 immunoreactive band identified in brain and PC12 cell
extracts also designated ERK4 [16,24]. This 45-kDa proteinmay
correspond to ERK1b, an alternatively spliced variant of ERK1
with a small insertion at the C-terminus [25].
Comparative genomic analyses revealed that MAPK6 and
MAPK4 (human ERK4 gene official name) display a similar
organization of exon/intron boundaries, which is different from
that of genes encoding conventional MAP kinases and related
protein kinases [21]. The high amino acid identity between
ERK3 and ERK4 in the kinase domain, together with their
conserved genomic organization, strongly suggest that the
MAPK6 and MAPK4 genes arose by duplication of a common
ancestor. Contrary to conventional MAP kinases, no gene
encoding ERK3 or ERK4 orthologs has been found in
invertebrates or in plants. Zebrafish and other teleost fishes
encode an ortholog of both ERK3 and ERK4 [26]. Thus,
available evidence suggests that ERK3 and ERK4 MAP kinase
genes are restricted to chordates or vertebrates.
3.2. Structure of ERK3 and ERK4 proteins
ERK3 and ERK4 contain a kinase domain at their N-
terminus followed by a C-terminal extension (Fig. 2). The firstFig. 2. Schematic representation of humanMAP kinases structure. MAP kinases are c
of varying lengths. The identity of the kinase domain with ERK1 is indicated.
transactivation domain; NLS: nuclear localization sequence; C34: conserved region in
kinases are shown on scale.150 residues of the C-terminal extremity of the two proteins are
nearly 50% identical, whereas the extreme C-terminus is
divergent. However, the C-terminus of ERK3 and ERK4 are
conserved throughout vertebrate evolution, suggesting an
important function. ERK3 and ERK4 display respectively
45% and 42% amino acid identity to ERK1 in the kinase
domain. Despite this similarity, two major features distinguish
ERK3/ERK4 from conventional MAP kinases. First, ERK3 and
ERK4 contain a single phospho-acceptor site (Ser–Glu–Gly) in
their activation loop, instead of the conserved Thr–Xaa–Tyr
motif. Predictably, ERK3 was found to be a poor substrate for
dual-specificity MAPKK family members [27,28]. Second, all
ERK3 and ERK4 orthologs have the sequence Ser–Pro–Arg
instead of Ala–Pro–Glu in subdomain VIII of the kinase
domain. Intriguingly, ERK3 and ERK4 are the only kinases in
the human genome to have an arginine residue at this position
[29]. The impact of these features on the regulation and
functions of ERK3/ERK4 is currently unknown.
More than 93% of human protein kinases contain a glutamic
acid residue in subdomain VIII, a degree of conservation similar
to catalytic residues [29]. Crystallographic data indicate,
however, that this residue is not involved in catalysis but
rather plays a structural role. The Glu residue of the APE
motif forms an ion pair with a highly conserved arginine
found in subdomain XI, thereby stabilizing the C-terminal
lobe of the kinase domain. This interaction is easily seen in the
X-ray structure of ERK2 (Fig. 3B) [30]. The C-terminal lobe
is involved in substrate binding and this conserved ion pair is
proposed to stabilize the interaction of the kinase with its
substrate [31]. In support of this idea, mutation of subdomain
VIII glutamic acid in protein kinase A markedly decreases its
affinity for substrates [32]. Besides arginine, aspartic acid,
asparagine and glutamine residues can be found at this
position in human kinases [29]. The crystal structure of CDK5omposed of a kinase domain (in blue) flanked with N- and C-terminus extensions
The activation loop phosphorylation motif is shown for each kinase. TAD,
ERK3/4; AHQr, alanine (A), histidine (H) and glutamine (Q) rich domain. MAP
Fig. 3. Subdomain VIII participates in the stabilization of the C-terminal lobe of the kinase domain. (A) Sequence alignment of subdomains VIII, IX, and XI of ERK3,
ERK2, CDK5 and CK1delta. SPR motif and subdomain XI-arginine are highlighted in turquoise and green, respectively. Residues contributing to the hydrogen bond
network of subdomain VIII are underlined. (B) Details of the interactions involving subdomain VIII. Important residues and polar interactions (broken green lines) are
shown. In ERK2, subdomain VIII-Glu 195 interacts with subdomain XI-Arg 299. Similarly in CDK5, subdomain VIII-Asp 171 interacts with subdomain XI-Arg 274.
In both cases, the arginine also interacts with residues in subdomains IX and XI. The hydrogen bond network seen in the casein kinase 1 family is different. As shown
for CK1delta, subdomain VIII-Asn 183 does not directly interact with subdomain XI. However, these two subdomains are connected via interactions with subdomain
IX. Subdomain IX binds both subdomain VIII (via the SIN motif) and subdomain XI (via Arg 256 and Leu 258). ERK3 structure was modeled with the Swiss-Model
server using active ERK2 (2ERK) as template [36]. The model predicts that subdomain VIII-Ser 199 interacts with the conserved subdomain XI-Arg 304, which may
result in the stabilization of ERK3 C-terminal lobe. The position of the SPR Arg 201 is uncertain. The pdb files used were: ERK2, 2ERK [30]; CDK5, 1H4L [33];
CK1delta, 1CKI [34]. The figure was generated using SPDBV 3.7 [35].
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VIII) reveals that aspartic acid also forms a salt bridge with
subdomain XI Arg residue (Fig. 3B) [33]. Casein kinase 1
isoforms have an asparagine in subdomain VIII and do not
possess the subdomain XI arginine residue (Fig. 3A). Never-
theless, structural data show that the C-terminal lobe of CK1
delta is stabilized by an alternative network of polar
interactions (Fig. 3B) [34]. These observations clearly indicate
that protein kinases can accommodate non-Glu residues in
subdomain VIII without compromising enzymatic activity.
Sequence alignment suggests that ERK3 and ERK4 possess
the subdomain XI arginine, much like APE-containing kinases
(Fig. 3A). In the absence of crystal structure, it is possible topredict the structure of ERK3 by homology modeling using the
crystal structure of phosphorylated ERK2 as template [35,36].
The modeled ERK3 kinase domain is predicted to fold with a
topology similar to other MAP kinases [37]. Themodel structure
shows that subdomain XI Arg 304 and subdomain VIII Arg 201
cannot interact because of electrostatic repulsion. However, Arg
304 is predicted to form a hydrogen bond with Ser 199 of the
SPR motif, which may contribute to the stabilization of the C-
terminal lobe of the kinase (Fig. 3B). The exact position of Arg
201 is uncertain and it does not interact with other residues in the
model. The elucidation of the X-ray structure of ERK3/ERK4
will be necessary to understand the molecular basis of their
catalytic activity and substrate specificity.
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ERK3 mRNA is expressed ubiquitously in adult mammalian
tissues [UniGene]. The highest expression is found in brain,
skeletal muscle and gastrointestinal tract. In the mouse, the
expression of ERK3 increases markedly between embryonic
days 9 and 11 of development, coincident with the period of
early organogenesis [19]. In vitro studies have showed that
ERK3 mRNA is up-regulated upon differentiation of P19
embryonal carcinoma cells to the neuronal or muscle lineage
[16]. These observations point to a possible role for ERK3 in
vertebrate embryogenesis. ERK3 also accumulates during
differentiation of model cell lines into neurons and myotubes
[37]. The mechanistic details of ERK3 gene regulation remain
largely unexplored. A transcriptional profiling study identified
ERK3 as one of the genes that are significantly up-regulated
in response to proteasome inhibitor treatment [38]. These
authors further suggested that ERK3 induction by proteasome
inhibition is dependent on p38 MAP kinase activity. However,
the generality of this observation needs to be examined further.
Analysis of EST databases indicates that ERK4 mRNA
expression is restricted to the brain, colon, eye, heart, kidney,
lung, ovary, pancreas, placenta, prostate, and skin. The highest
expression is found in the brain [22,39]. Nothing is known
about the regulation of ERK4 gene expression.
ERK3 was found to be a highly unstable protein, with a half-
life of 30–45 min in exponentially proliferating cells [37,40].
This provided the first documented example of a MAP kinase
family member whose activity is acutely regulated by protein
turnover. The proteolysis of ERK3 is executed by the
proteasome and is dependent on the polyubiquitination of the
protein. Treatment with proteasome inhibitors or inactivation of
the ubiquitin-activating enzyme (E1) results in the accumulation
of endogenous or ectopically-expressed ERK3 protein. The
turnover of ERK3 is independent of its activation loop
phosphorylation, enzymatic activity or C-terminal extension.
Analysis of a series of chimeras made between the stable ERK1
kinase and ERK3 delimited two degrons in the N-terminal lobe
of ERK3 kinase domain that are both necessary and sufficient to
target ERK3 for proteasomal degradation [37]. Importantly, the
stability of ERK3 is also regulated by the cellular context. For
example, accumulation of ERK3 during differentiation of
C2C12 myoblasts into muscle cells is associated with the
time-dependent stabilization of the protein [37]. This suggests
that protein turnover may play a key role in the regulation of
ERK3 biological functions. In contrast, ERK4 is a highly stable
protein (Rousseau, J. and Meloche, S., unpublished data),
thereby revealing a major difference between the two kinases of
this subfamily.
Most substrates of the ubiquitin-proteasome pathway are
conjugated to ubiquitin via an internal lysine residue [41,42].
Interestingly, recent evidence suggests that ERK3 is targeted for
degradation via an alternative mode of ubiquitination, involving
the conjugation of a polyubiquitin chain to the free NH2
terminus of the protein [43]. Surprisingly, a lysine-less mutant
of ERK3 (ERK3-0K) was shown to be ubiquitinated and
degraded by the proteasome with kinetics comparable to thewild type protein. Genetic analysis confirmed that proteolysis of
ERK3-0K is dependent on its ubiquitination. The N-terminal
ubiquitination of ectopically expressed ERK3 was directly
documented by mass spectrometry. Thus, ERK3 adds to a
growing list of protein substrates that are conjugated to the first
ubiquitin moiety through the α-NH2 group of their N-terminal
residue [44]. The ubiquitin ligase (E3) implicated in ERK3 N-
terminal ubiquitination is unknown.
At the subcellular level, ERK3 is found in both the cyto-
plasmic and nuclear compartments of a variety of exponentially
proliferating cells [20,45–47]. Unlike conventional MAP
kinases, exposure of cells to common mitogenic stimuli or
chemical stresses does not cause the relocalization of ERK3 to a
distinct subcellular compartment [45]. The cellular distribution
of ERK3 is also independent of activation loop phosphorylation
or enzymatic activity. ERK3 is imported into the nucleus by an
active temperature-dependent mechanism, and is exported to
the cytoplasm in part by a CRM1-dependent active mechanism
[45]. Biochemical studies have shown that recombinant ERK3
directly binds to the exportin CRM1 in vitro. ERK3 was also
reported to localize to the endoplasmic reticulum Golgi
intermediate compartment (ERGIC)/cis-Golgi, and it has been
suggested that translocation of the kinase from the Golgi to the
nucleus is contingent upon proteolytic removal of a C-terminal
fragment [20]. Preliminary studies indicate that the subcellular
distribution of ERK4 differs from that of ERK3. In many cell
types examined, ERK4 is predominantly localized in the
cytoplasm (unpublished data).
Two recent studies have shown that ERK3 interacts with the
MAP kinase-activated protein kinase MK5 [46,47]. Interest-
ingly, co-expression of ERK3 and MK5 causes the redistribu-
tion of both proteins from the nucleus to the cytoplasm. On the
other hand, downregulation of MK5 expression leads to a
dramatic reduction in ERK3 protein levels, suggesting that
MK5 acts as a chaperone for ERK3. The physiological
significance of these observations is not clear.
3.4. Mechanism of activation of ERK3 and ERK4
Little is known about the regulation of ERK3 and ERK4
enzymatic activity. Metabolic labeling experiments and immu-
noblotting analysis with a phospho-specific antibody have
shown that ERK3 is phosphorylated on activation loop Ser 189
in intact cells [37,43,48]. A catalytically inactive mutant of
ERK3 is phosphorylated to the same extent as the wild-type
protein, indicating that phosphorylation of Ser 189 is executed
in trans by a cellular ERK3 kinase [43]. A protein kinase
capable of binding ERK3 and phosphorylating it on Ser189 has
been identified and partially purified from rabbit muscle [49].
The ERK3 kinase was found to be highly specific as
demonstrated by its inability to phosphorylate ERK1, ERK2,
or ERK2 mutants that mimic ERK3 in the activation loop.
In contrast with conventional MAP kinases, the phosphor-
ylation of ERK3 in the activation loop is constitutive in serum-
starved cells and is not further increased by exposure to growth
factors or chemical stresses (Coulombe, P. and Meloche, S.,
manuscript in preparation). An important question that remains
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ERK3 correlates with enzymatic activity.
3.5. Substrates and physiological functions of ERK3 and ERK4
The recombinant ERK3 protein purified from E. coli is
capable of autophosphorylating on Ser 189 in vitro, demon-
strating that ERK3 has intrinsic phosphotransferase activity
([48]; unpublished data). Moreover, a chimeric kinase contain-
ing the N-terminal domain of ERK3 (subdomains I–V) and the
C-terminal half of the ERK2 catalytic core displays relatively
high specific activity towards the ERK2 substrate myelin basic
protein (MBP), further indicating that ERK3 binds ATP in a
manner appropriate for catalysis [50]. However, ERK3, either
expressed in bacteria or immunoprecipitated from cultured
cells, did not phosphorylate a panel of generic protein kinase
substrates in vitro ([48]; unpublished data). More recently,
ERK3 was reported to bind to and phosphorylate MK5 in the
activation loop, leading to the activation of the kinase [46].
However, another group suggested that ERK3 promotes MK5
autophosphorylation instead [47]. Additional work is required
to resolve this discrepancy and clarify whether MK5 is a bona
fide ERK3 substrate.
Why does ERK3 kinase activity has been so difficult to
demonstrate experimentally? Sequence analysis and structural
modeling may help understand the distinct substrate specificity
of ERK3. Crystallographic data reveal that phosphorylated
residues in the activation loop of kinases interact in an intra-
molecular fashion with phosphate binding sites located near the
loop [51]. The phosphorylated Thr–Xaa–Tyr motif of conven-
tional MAP kinases interacts with so-called primary and
secondary phosphate binding sites. The primary site, also
known as the RD pocket, is defined by three highly conserved
Arg residues that coordinate the phosphate of the threonine, as
seen in the structure of di-phosphorylated ERK2 (Fig. 4) [30].
Similarly, the phospho-tyrosine interacts with the secondary
phosphate binding site composed of two conserved arginine
(Fig. 4). Sequence alignment indicates that ERK3 possesses the
three arginine of the primary site (Fig. 4A). Intriguingly, ERK3
also has the two positively charged residues of the secondary
phosphate binding site (Fig. 4A). Because ERK3 only has the
primary phosphorylation site (Ser 189), the function of the
putative secondary binding site is unclear. Other protein kinases
also have “extra” phosphate binding sites. For example, GSK3β
only has the second tyrosine phosphorylation site in its
activation loop (Fig. 4A). Sequence analysis indicates, however,
the presence of both the primary and secondary phosphate
binding sites in GSK3β (Fig. 4A). The crystal structure of
GSK3β shows that the secondary site is occupied by the
phospho-tyrosine as in the case of ERK2 (Fig. 4B) [52]. Notably,
the primary site is filled with a sulfate anion, indicating that it is
functional (Fig. 4B). What is then the role of the primary site?
GSK3β is known to require phosphate priming of its substrates
at the P+4 position for efficient recognition [53]. It is thought
that the primary site of GSK3β interacts directly with the primed
phosphorylated substrate, thus positioning it at the active site. In
agreement with this idea, mutation of one of the three positivelycharged residues of the primary site impairs GSK3β activity
towards phosphorylated substrates, but has no impact on non-
primed substrates [53]. The yeast SR-kinase Sky1p also has a
secondary phosphate binding site, even though this enzyme does
not require activation loop phosphorylation for activity (Fig. 4A)
[54]. Like GSK3β, biochemical data suggest that Sky1p acts in a
processive manner on pre-phosphorylated substrates [51,55].
These examples of CMGC kinases show that phosphate binding
sites may dictate substrate specificity. These enzymes are some-
times referred to as phosphate-directed kinases.
Similarly, the secondary phosphate binding site of ERK3
could enable the kinase to act on primed phosphorylated
substrates. To further test this possibility, we generated a model
of ERK3 phosphorylated on Ser 189 based on di-phosphory-
lated ERK2 (Fig. 4B). The model clearly shows that ERK3
primary site interacts with phospho-Ser 189, arguing that this
phosphorylation event leads to ERK3 activation. The predicted
structure also suggests that the secondary site of ERK3 is
functional and could chelate an anion, like the phosphate ion
modeled in Fig. 4B. If ERK3 has phosphate-directed specificity,
this would explain the lack of kinase activity detected in vitro
towards non-phosphorylated substrates. Future biochemical and
structural studies will clarify these issues.
The phenotype of ERK3 and ERK4 deficient mice has not
been reported and the physiological functions of these kinases
remain to be defined. Several lines of evidence suggest a role for
ERK3 in the control of cell differentiation. For example, ERK3
mRNA and protein levels are up-regulated during terminal
differentiation of P19 [16], PC12 [37] and C2C12 [37] cell lines
in vitro. Differentiation of these model cell lines is associated
with G1 arrest of the cell cycle. ERK3 expression is also
induced following treatment of Raji lymphoma cells with
inhibitory gangliosides [56] or after plating of squamous cell
carcinoma lines on type IV collagen [57], two conditions
associated with inhibition of cell proliferation. These observa-
tions suggest that ERK3 may act as a negative regulator of cell
cycle progression in certain cellular contexts, thereby facilitat-
ing cell differentiation. In agreement with this idea, over-
expression of ERK3 was found to inhibit S phase progression of
various cell types [37,45,57]. However, the putative effects of
ERK3 on cell cycle progression and cellular differentiation need
to be validated by loss-of-function studies. It has been recently
suggested that ERK3 is involved in glucose-induced insulin
secretion [58]. Treatment with prolactin was shown to induce
ERK3 mRNA and protein levels in isolated pancreatic islets.
Downregulation of ERK3 expression by antisense oligonucleo-
tides abolished the insulin secretion stimulated by glucose in rat
islets. Measurement of insulin and glucose levels in ERK3
deficient animals will provide rigorous testing of the involve-
ment of ERK3 in glucose metabolism.
4. NLK subfamily
4.1. Discovery of NLK enzyme
Drosophila nemo was discovered in 1994 as a gene required
for proper photoreceptor cells rotation during ommatidia
Fig. 4. Structural modeling suggests that ERK3 might be a phosphate-directed kinase. (A) Sequence alignment of the residues involved in the formation of the
phosphate binding sites of ERK3, ERK2, GSK3β and Sky1p. Residues forming the primary and the secondary phosphate binding sites are highlighted in turquoise and
in green, respectively. Note that ERK3 is predicted to have both sites. One arginine of the putative secondary site is substituted with a lysine in ERK3. The activation
loop is underlined. (B) Structural details of the phosphate binding sites. Important residues forming the primary and the secondary sites are shown. Hydrogen bonds
between amino acid residues and anions are depicted by green broken lines. The position of the active site (AS) located near the catalytic aspartic acid is indicated. In
GSK3β and Sky1p, the structure contains a sulfate anion (S) located in the primary and secondary site, respectively. The tertiary structure of activated ERK3 was
modeled with the Swiss-Model server using di-phosphorylated ERK2 (2ERK) as template. Phosphate ions were introduced in both phosphate binding sites, using
active ERK2 as a guide. The predicted secondary site of ERK3 can form four hydrogen bonds with the phosphate (P ?). The pdb files used were: ERK2, 2ERK [30];
GSK3β, 1GNG [52]; Sky1p, 1HOW [54]. The figure was made using SPDBV 3.7 [35].
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encode a serine/threonine kinase with homology to MAP
kinases. Four years later, the murine ortholog of Nemo was
isolated by PCR cloning using degenerate primers based on
MAP kinase family sequences [60]. The murine gene product
was denoted NLK, because of its similarity to Drosophila
Nemo. An ortholog of NLK, known as LIT-1, was also
identified in C. elegans as a gene product that interacts
genetically with the Wnt signaling pathway [61,62].
4.2. Structure of NLK protein
Human NLK is a 515-amino acid protein with a central
kinase domain bordered by N- and C-terminal extensions of
∼100 residues (Fig. 2A). The extended N-terminus has a
unique sequence that is highly enriched in alanine, glutamine,and histidine residues. However, this region of the kinase is
poorly conserved among NLK orthologs and its function
remains obscure. The C-terminal extension is conserved from
worm to human (45% identity between LIT-1 and human NLK)
and may contribute to the interaction of the kinase with specific
substrates or targets [63–65]. The kinase domain of NLK
displays more sequence similarity to the MAP kinases (45%
identity with ERK2) than to CDKs (38% identity with CDK2).
Like ERK3 and ERK4, NLK lacks the tyrosine phosphorylation
site in its activation loop. The TQE motif found in NLK
resemble the THE sequence of CDK2.
4.3. Regulation of NLK expression and localization
In the mouse, NLKmRNA is expressed in most adult tissues,
with the highest levels seen in brain and lymphoid organs ([60];
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characterized. Ectopically expressed NLK is found predomi-
nantly in the nucleus with some diffuse expression in the
cytoplasm [60,66]. It is not known whether activation of NLK
influences its cellular distribution.
4.4. Mechanism of activation of NLK
Based on its homology to MAP kinases and cyclin-
dependent kinases, NLK is predicted to be regulated by
phosphorylation of its activation loop Thr 286. Surprisingly,
there is no published biochemical data confirming that this site
is phosphorylated in vivo. However, mutation of Thr 286
abolishes the ability of NLK to autophosphorylate and to induce
the degradation of c-Myb, indicating that activation loop
phosphorylation is necessary for its activity [60,66].
NLK is activated by various extracellular ligands, notably
the Wnt ligand Wnt-1, the cytokines interleukin-6 and
granulocyte colony-stimulating factor, and transforming growth
factor-β (TGF-β) family members [66–69]. In certain cell
types, elevation of intracellular Ca2+ is sufficient to stimulate
NLK enzymatic activity, by a mechanism dependent on Ca2+/
calmodulin-dependent protein kinase II activation [70]. Genetic
and biochemical evidence have implicated the MAPKKK TGF-
β-activated kinase 1 (TAK1) and its regulatory subunit TAK1-
binding protein 1 (TAB1) in NLK activation [62,63,67,68,71].
However, it remained unclear whether an intermediate kinase is
functioning between the MAPKKK TAK1 and the MAP kinase
NLK. More recently, homeodomain-interacting protein kinase
(HIPK2), a member of the CMGC group of protein kinases, was
shown to interact with and phosphorylate NLK in vitro [66].
HIPK2 is a large nuclear protein kinase that was originally
identified as a co-repressor for homeodomain transcription
factors [72]. The phosphorylation of NLK by HIPK2 is
associated with an increase in phosphotransferase activity.
However, the phosphorylation site(s) of NLK has not been
characterized and it is presently unclear whether HIPK2 directly
phosphorylates NLK in the activation loop or induces its
autophosphorylation. In addition, TAK1 was shown to
phosphorylate HIPK2 in vitro, although phosphorylation did
not translate into enzymatic activation [66]. These findings
suggest that HIPK2 may represent the missing MAP kinase
kinase (distinct from MAPKK/MEK family members) in the
TAK1-NLK signaling pathway (Fig. 1).
4.5. Substrates and physiological functions of NLK
Immunoprecipitated NLK does not phosphorylate generic
MAP kinase or CDK substrates in vitro, suggesting that it has
different or more restricted substrate specificity [60]. In the past
few years, a number of transcription factors were shown to be
regulated by NLK phosphorylation. The first NLK substrates to
be identified are members of the T-cell factor (TCF)/lymphoid
enhancer factor (LEF) family, which are ultimate mediators of
the Wnt signaling pathway [73]. Genetic analyses of endoderm
specification in C. elegans have revealed that lit-1 negatively
regulates pop-1 (which encodes a TCF/LEF related protein)activity and that mutations in pop-1 are epistatic to mutations in
lit-1 [61,62,74]. A biochemical explanation for these observa-
tions came with the finding that LIT-1/NLK associate with and
phosphorylate TCF/LEF proteins in vitro [61,63]. The func-
tional consequence of this phosphorylation is to relocalize TCF
to the cytoplasm and/or prevent its binding to target gene
promoters. Further biochemical characterization indicated that
NLK phosphorylates LEF-1 and TCF-4 on two conserved
serine and threonine residues that are followed by a proline [70].
Phosphorylation sites of other NLK substrates (see below) were
also found to be followed by a proline, demonstrating that NLK
has proline-directed specificity like conventional MAP kinases.
Recently, the RING finger protein NARF was isolated from a
yeast two-hybrid screen as an NLK-interacting protein [65].
NARF catalyzes the ubiquitination of TCF/LEF members in
vitro and it has been suggested that ubiquitination and
degradation of TCF/LEF is contingent upon their phosphoryla-
tion by NLK.
The NLK pathway plays a critical role in TGF-β-induced
mesodermal development in Xenopus embryos [67]. Biochem-
ical studies have shown that NLK associates with and
phosphorylate the transcriptional regulator STAT3 on its C-
terminal Ser 727 residue [67,69]. In vivo depletion studies in
Xenopus embryos indicated that NLK is involved in serine
phosphorylation of endogenous STAT3 and that both serine and
tyrosine phosphorylation of STAT3 C-terminus are necessary
for mesoderm induction [67]. NLK was also shown to
phosphorylate the Myb family members c-Myb and A-Myb at
multiple sites [66,75]. In the case of c-Myb, phosphorylation by
NLK promotes its ubiquitination and proteasome-dependent
degradation in vivo, resulting in inhibition of c-Myb-dependent
transcription [66].
The gene encoding NLK has been disrupted in mice by
insertion of a lacZ cassette into the kinase domain [7]. The
phenotype of Nlk−/− mice is modulated by the genetic
background; whereas NLK-null mice die during the third
semester of pregnancy in a C57BL/6 background, mutant mice
bred to a 129/Sv background survive for up to 4–6 weeks. The
latter Nlk−/− mice are growth retarded and suffer from
neurological abnormalities. Histopathological examination
revealed that NLK deficient mice have a compromised
hematopoietic system, characterized by lymphopenia and
abnormal differentiation of bone marrow stromal cells.
Surprisingly, no intrinsic defect of lymphocyte development
was documented in these mice. Given the roles of the Wnt and
STAT3 signaling pathways in development, the phenotype of
NLK mutant mice is milder than expected. This suggests the
existence of functional redundancy in the NLK signaling
pathway that can genetically compensate for the loss of the
kinase.
5. ERK7 subfamily
5.1. Discovery of ERK7 enzyme
ERK7 was cloned in 1999 by PCR amplification of a rat
brain cDNA library using degenerate primers based on
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same group reported the cloning of a human kinase with high
similarity to ERK7, which they named ERK8 [77]. The rat
ERK7 and human ERK8 sequences share 69% amino acid
identity overall (82% in the kinase domain), which is lower than
the homology typically observed between other rodent and
human MAP kinase orthologs. However, analysis of the human
kinome did not reveal the presence of another kinase more
similar to ERK7 [13]. Furthermore, phylogenetic analyses
indicated that a single gene encoding ERK7 is present in
metazoan and also in the social amoeba Dictyostelium
discoideum (unpublished data). Intriguingly, this kinase is
significantly less conserved across evolution as compared with
other MAP kinases. For example, zebrafish ERK7 is 51%
identical to the human kinase, whereas ERK1 shows more than
90% similarity between the two species. The evidence indicates
that all these kinases are true ERK7 orthologs. Hence, we will
refer to the human kinase as ERK7 in this review.
5.2. Structure of ERK7 protein
Human ERK7 is a 544-amino acid protein with an N-
terminal kinase domain similar to MAP kinases and a C-
terminal extension of 204 residues (Fig. 2). The kinase domain
of ERK7 is 45% identical to ERK1. The C-terminal region does
not show any significant similarity to other proteins. Notably, it
contains two proline-rich regions that may represent SH3
domain ligands, and a putative nuclear localization sequence
(NLS). Like ERK1/ERK2 and ERK5, ERK7 contains the TEY
motif in its activation loop (Fig. 2).
5.3. Regulation of ERK7 expression and localization
Human ERK7 mRNA is widely expressed in adult tissues,
with predominant expression seen in lung and kidney ([77];
UniGene). Similar to ERK3, the activity of ERK7 appears to be
controlled by protein turnover [78]. Ectopically expressed
ERK7 is rapidly ubiquitinated and degraded by the proteasome
in proliferating cells, with a half-life of ∼2 h. Analysis of a
series of chimeras between ERK2 and ERK7 revealed that the
N-terminal 20 amino acids of the kinase domain (subdomain I)
are necessary and sufficient to signal ERK7 degradation. ERK7
is stabilized by overexpression of an N-terminal mutant of
Cullin-1, suggesting the involvement of an SCF family E3
ligase in mediating ERK7 ubiquitination.
Overexpressed ERK7 protein is predominantly found in the
nucleus [76]. The subcellular localization of the kinase is
independent of its catalytic activity. Deletion of the C-terminal
extension of ERK7 results in some redistribution of the protein
to the cytoplasm, consistent with the presence of a putative NLS
in that region. The localization of the endogenous protein is
unknown.
5.4. Mechanism of activation of ERK7
The regulation of ERK7 enzymatic activity is unique among
MAP kinases. Ectopically expressed rat ERK7 is constitutivelyphosphorylated on the activation loop Thr–Glu–Tyr motif in
vivo, and displays significant kinase activity against various
MAP kinase substrates [14,76]. Notably, the catalytically-
inactive K43R mutant of ERK7 is not phosphorylated on the
TEY motif in cells, suggesting that activation loop phosphor-
ylation results from an autophosphorylation event [76]. In
strong support of this idea, it was shown that recombinant
ERK7 expressed in E. coli is phosphorylated on both threonine
and tyrosine residues of the TEY motif and exhibits high
specific activity towards exogenous substrates [14,15]. In
contrast, catalytically-inactive mutants of ERK7 were not
phosphorylated on these sites. Surprisingly, the activity of
bacterially expressed human ERK7 is decreased by 95% after
treatment with the serine/threonine-specific phosphatase PP2A,
but only by 15% after treatment with a tyrosine-specific
phosphatase [15]. This suggests that phosphorylation of the
threonine residue is the major determinant of ERK7 activity.
Indeed, when overexpressed in 293 cells, human ERK7 displays
100-fold less activity than the recombinant purified kinase and
is found monophosphorylated on tyrosine [15]. Treatment with
the serine/threonine phosphatase inhibitor okadaic acid induces
threonine phosphorylation of the kinase and stimulates its
enzymatic activity. These findings suggest that the activity of
ERK7 is determined by the relative rates of ERK7 autopho-
sphorylation and its dephosphorylation on the activation loop
threonine. Although not limiting, tyrosine autophosphorylation
is nevertheless required for ERK7 activity based on the
observation that the TEF mutant is inactive. Additionally,
mutagenesis studies have suggested that the C-terminal
extension of ERK7 is required for its full activation [76].
How physiological agonists regulate ERK7 activity is
unclear. It was originally reported that the extent of phosphor-
ylation and activity of the kinase are not increased following
stimulation with growth factors, phorbol ester or chemical
stresses [76]. Subsequent studies showed however that
oxidative stress and mitogens stimulate the activation loop
phosphorylation of ERK7 [15,77]. Activated Src and RET
tyrosine kinases were also found to induce ERK7 phosphoryla-
tion and activation [77,79]. Notably, ERK7 was found to
physically associate with Src in cells. It is unclear whether
tyrosine kinase signaling stimulates a MAP kinase kinase or
instead inhibits a phosphatase dedicated to ERK7.
5.5. Substrates and physiological functions of ERK7
ERK7 phosphorylates the classical ERK1/2 substrate MBP
in vitro [76,77]. Interestingly, the major residues in MBP
phosphorylated by ERK7 were identified as Ser 126 and Thr 94,
two residues followed by a proline, which are distinct from the
site phosphorylated by ERK2, namely Thr 97 [9,15]. This
indicates that ERK7 is a proline-directed kinase, but with a
distinct substrate specificity than ERK1/2. The physiological
substrates of ERK7 remain to be identified.
The physiological functions of ERK7 are unknown. The
phenotype of ERK7 deficient mice has not been reported yet.
Published studies suggest that ERK7 may play a role in the
regulation of cell proliferation, chloride transport and nuclear
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inhibits S-phase entry in CV-1 cells [76]. Intriguingly, this
effect was found to be independent of ERK7 kinase activity but
to require an intact C-terminus. Loss-of-function experiments
are necessary to confirm that endogenous ERK7 exerts anti-
proliferative actions. The transmembrane protein chloride
intracellular channel 3 (CLIC3) was isolated in a yeast two-
hybrid screen using the C-terminal extension of ERK7 as bait
[80]. CLIC3 is a member of a family of small proteins proposed
to function as chloride channels [81]. Biochemical data
indicated that ERK7 is not able to phosphorylate CLIC3 in
vitro, although the situation may be different in the in vivo
context. It is not known whether ERK7 influences CLIC3
chloride transport activity.
In recent years, evidence has accumulated that ERK7 may
regulate nuclear receptor signaling. Ectopic expression of
ERK7 was shown to decrease the steady-state levels of estrogen
receptor alpha (ERα) by promoting its degradation by the
proteasome [82]. This effect of ERK7 is dependent on its
catalytic activity, although direct phosphorylation of ERα was
not demonstrated. Intriguingly, immunoblot analysis of a small
panel of normal and tumor breast tissues suggested that breast
cancer progression is correlated with loss of ERK7 expression
[82]. These observations will need to be validated on larger
cohorts of patients using immunohistochemistry techniques.
More recently, hydrogen peroxide inducible clone-5 (Hic-5)/
androgen receptor activator-55 (ARA55) was identified as an
ERK7 interacting protein in a yeast two-hybrid screen [83]. Hic-
5 is a LIM domain containing co-activator of the androgen
receptor (AR), glucocorticoid receptor alpha (GRα), progester-
one receptor (PR) and peroxisome proliferator-activated
receptor gamma (PPARγ) nuclear receptors [84–86]. Gene
reporter assays showed that overexpression of ERK7 negatively
regulates the transcriptional co-activation of AR and GRα by
Hic-5 in heterologous cells. This effect is independent of the
kinase activity of ERK7. Reciprocally, silencing of endogenous
ERK7 in airway epithelial cells enhanced dexamethasone-
stimulated transcriptional activity of GRα.
6. Concluding remarks
The MAP kinases ERK3 and ERK4 were identified contem-
porary to the archetype MAP kinase ERK2, but have received
much less attention by the signaling community. Similarly, less
progress has been made towards understanding the regulation
and functions of the more recently identified MAP kinases NLK
and ERK7. However, recent studies have started to shed some
light on the biological properties of these enzymes. The
observation that ERK3 and ERK7 are constitutively degraded
by the ubiquitin-proteasome pathway has highlighted a novel
mode of regulation of these MAP kinases. NLK and ERK7 have
been shown to have proline-directed specificity and physiolo-
gical substrates of NLK have been identified in different
species. Biochemical studies have demonstrated the unique
mechanism of ERK7 activation by autophosphorylation.
However, several important questions remain unanswered. For
instance, the substrate specificity of ERK3 and ERK4 isunknown. No substrate of these enzymes has yet been
identified, which severely hampers the study of their regulation
and biological functions. Another aspect of the regulation of
ERK3 and ERK4 that is currently unclear is how phosphoryla-
tion controls enzymatic activity. The identification of the kinase
responsible for activation loop phosphorylation of ERK3 and
ERK4 would also help understand the regulation of their
activity. Finally, little is known about the physiological
functions of atypical MAP kinases. Gene targeting studies in
the mouse and RNA interference experiments will be instru-
mental in this regard.
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